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ABSTRACT The aim was to evaluate susceptibility of oropharyngeal contamination with various
bronchoscopic sampling techniques.
67 patients with obstructive lung disease and 58 control subjects underwent bronchoscopy with small-
volume lavage (SVL) through the working channel, protected bronchoalveolar lavage (PBAL) and bilateral
protected specimen brush (PSB) sampling. Subjects also provided an oral wash (OW) sample, and negative
control samples were gathered for each bronchoscopy procedure. DNA encoding bacterial 16S ribosomal
RNA was sequenced and bioinformatically processed to cluster into operational taxonomic units (OTU),
assign taxonomy and obtain measures of diversity.
The proportion of Proteobacteria increased, whereas Firmicutes diminished in the order OW, SVL,
PBAL, PSB (p<0.01). The alpha-diversity decreased in the same order (p<0.01). Also, beta-diversity varied
by sampling method (p<0.01), and visualisation of principal coordinates analyses indicated that differences
in diversity were smaller between OW and SVL and OW and PBAL samples than for OW and the PSB
samples. The order of sampling (left versus right first) did not influence alpha- or beta-diversity for PSB
samples.
Studies of the airway microbiota need to address the potential for oropharyngeal contamination, and
protected sampling might represent an acceptable measure to minimise this problem.
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High-throughput sequencing has opened up a new window in microbial ecology, enabling the
characterisation of microbial communities in biological compartments thought to be completely sterile
only a few years ago. The implications for health and disease are widely unexplored, but are likely to be
significant [1]. Recent studies have found compelling evidence for the lungs to have a distinct microbiome [2],
providing a bacterial presence with which our immune system interacts [3, 4]. As almost all pulmonary
diseases have a local inflammatory component, there is a possibility of a disrupted microbiome being
integral to disease pathogenesis.
Thus, there is a current push to characterise the pulmonary microbiome, and its relation to different
pulmonary diseases. However, sampling the pulmonary microbiome is difficult. Sputum is fraught with
significant contamination from the oral cavity, and percutaneous sampling is unpractical with a high risk of
complications like pneumothorax or bleeding. The emerging gold standard for sampling is bronchoscopy.
But bronchoscopy also has its technical challenges, besides issues of discomfort, cost and sedation. The
bronchoscope must pass through either the oral or nasal cavity in addition to the pharyngeal cavity, and
might carry contaminants from the upper airways to the lower biomass compartment of the lower airways.
Samples are collected through the same bronchoscope working channel through which fluid is suctioned up
and out. The different modes of sampling (bronchoalveolar lavage (BAL) brushings, biopsies) might be
carried through catheters, which may or may not have a wax-sealed tip to ensure sterility. Added to this is
the conundrum caused by the constant influx of microbiota by microaspiration and inhalation that
probably is responsible for maintenance and creation of a large fraction of the lung microbiome [5].
In 25 studies of the human lung microbiome sampling the airway microbiome by bronchoscopy of healthy
subjects [2–4, 6–9] and patients with chronic obstructive pulmonary disease (COPD) [10–14], asthma
[15, 16], interstitial lung disease [17, 18], cystic fibrosis (CF) [19], HIV [20–23] and lung-transplanted
subjects [24–27]; only five used protected sterile brushes (PSB) to avoid contamination from the working
channel [7, 8, 16, 19, 22]. Some authors reported that suction was not used prior to entering the trachea
[2–4, 6–10, 20, 22], and three studies used separate bronchoscopes for anaesthesia and sampling of some
or all participants [3, 4, 7]. No study performed bronchoalveolar lavage (BAL) through a protected
catheter (protected BAL), and no study with more than 20 sampled subjects has compared protected with
unprotected sampling methods.
In preparation for the analyses of a large, ongoing COPD microbiome study [28], we sought to reduce
contamination as well as assess the performance of different sampling techniques. In the current paper we
present analyses to examine the degree of oropharyngeal influence on the airway microbiome applying
protected bronchoscopic sampling techniques. In addition we present an analysis on the effect of sampling
the left or right lung first.
Material and methods
The design of the entire MicroCOPD study has been published previously [28]. The current analysis
includes 58 control subjects, 64 subjects with COPD and three subjects with asthma. All participants were
at least 35 years old and were recruited from previous longitudinal case–control studies in addition to a
few volunteers [29]. Subjects had neither acute respiratory symptoms nor any reported use of antibiotics or
oral corticorticosteroids within the last 14 days prior to bronchoscopy. Other inclusion/exclusion criteria
are listed in the supplementary material.
The Regional Committee for Medical and Health Research Ethics approved the study (REK Nord, project
number 2011/1307). All participants provided written informed consent.
All participants received at least 0.4 mg of salbutamol through a spacer before the bronchoscopy
procedure. Flexible video-bronchoscopy was performed via the oral route in supine position. No suction
was used prior to having entered the trachea. All subjects received local anaesthesia with lidocaine both
before and during the procedure. All but 18 subjects received mild sedation (alfentanil) parenterally.
Participants were monitored according to current guidelines, and were observed for at least 2 h after the
procedure [30]. Six procedural samples, of which five were obtained during bronchoscopy, were analysed
for each participant: oral wash (OW); three protected specimen brushes (PSBs) from the right lower lobe
(right PSB) and three from the left upper lobe (left PSB); two 50-mL fractions of protected
bronchoalveolar lavage of the right middle lobe (PBAL1 and PBAL2); and small-volume lavage (SVL) in
the left upper lobe. In addition, we included negative control samples (NCSs) from the same bottle of
phosphate-buffered saline that was used for the procedure of the corresponding individual. For 49
subjects, we examined the left lung before the right lung. BAL and SVL were always collected after
obtaining PSB samples. Protected specimen brushes and protected bronchoalveolar lavage are illustrated in
supplementary figures S1 and S2.
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Bacterial DNA was extracted using a combination of enzymatic lysis with lysozyme, mutanolysin and
lysostaphin, and mechanical lysis methods using the FastPrep-24 as described by the manufacturers of the
FastDNA Spin Kit (MP Biomedicals, LLC, Solon, OH, USA).
Library preparation and sequencing of the V3-V4 region of the 16S rRNA gene was carried out according
to the Illumina 16S Metagenomic Sequencing Library Preparation guide (Part no. 15044223 Rev. B). The
V3-V4 region was PCR amplified (45 cycles) and prepared for a subsequent index PCR step using primers
adapted from KLINDWORTH et al. [31] as follows. 16S amplicon PCR forward primer (overhang adaptor
sequences are underlined): 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGG
NGGCWGCAG. 16S amplicon PCR reverse primer (overhang adaptor sequences are underlined):
5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC. The samples
were pooled and prepared for 2×300 cycles of paired-end sequencing on the Illumina Miseq sequencing
platform using reagents from the Miseq reagent kit v3 (Illumina Inc., San Diego, CA, USA).
The chosen bioinformatic pipeline was Quantitative Insights Into Microbial Ecology (QIIME, http://qiime.
org) v1.9.1. After creating a library of joined reads, operational taxonomic units (OTUs) were picked at a
97% similarity threshold, small OTUs and OTUs seen in negative control samples were removed,
taxonomy was assigned to the OTUs and a phylogenetic tree was constructed after alignment. We used the
GreenGenes version 13.8 as reference database [32]. Further details on the bioinformatic procedures can
be found in the supplementary material.
Differences in relative abundance of taxa were evaluated by applying a beta distribution and
non-parametric trend tests. Alpha-diversity was evaluated using Faith’s phylogenetic diversity (PD), or
“PD wholetree”. Beta-diversity was estimated with unweighted UniFrac and visualised by principal
coordinates analyses (PCoA) [33]. Diversity analyses require a similar number of sequences in each
sample, which was ensured by rarefaction. Statistical significance for alpha-diversity and beta-diversity
between sampling methods was evaluated by Bonferroni-corrected Wilcoxon matched-pairs test in Stata
version 13.2 (Statacorp, Texas, USA) and permutational ANOVA (permanova) tests in QIIME,
respectively.
Results
Only three subjects had asthma: two men and one woman. The 64 COPD subjects were slightly older,
included more men and had a larger tobacco-smoking burden than the 58 control subjects (table 1).
For each of the 125 participants, seven samples were sequenced (negative control sample, OW, right PSB,
PBAL1, PBAL2, left PSB, SVL). A total of 12.5 million sequences were obtained from the six procedural
samples after bioinformatics clean-up, as described in the methods section. For alpha- and beta-diversity,
we rarefied our data at 1000 sequences.
Taxonomy
Figure 1 shows the taxonomic classification by sampling method at the phylum level. As the degree of
protection from influence of oral environment increased, the proportion of Proteobacteria increased,
whereas Firmicutes diminished (p<0.01). At the genus level all sample types where dominated by
streptococci, but the mean proportion of the largest Streptococcus OTU showed the same declining pattern
by sample type (OW 14.5%, SVL 13.6%, PBAL1 11.8%, PBAL2 11.3%, right PSB 8,6% and left PSB 5.4%;
non-parametric trend test p<0.001).
TABLE 1 Characteristics of 125 subjects of the MicroCOPD study
COPD Asthma Control
Subjects 64 3 58
Males 34 (53.1%) 2 (67.7%) 34 (58.6%)
Current smokers 15 (23.4%) 0 16 (27.6%)
Ex-smokers 48 (75.0%) 2 (67.7%) 35 (60.3%)
Never-smokers 1 (1.6%) 1 (33.3%) 7 (12.1%)
Smoking exposure pack-years 28.49±16.08 20.88±24.22 22.83±18.55
FEV1 % predicted 56.83±16.30 88.31±11.37 100.71±11.00
Age years 68.73±7.23 64.41±9.1 64.89±8.43
Use of inhaled corticosteroids 44 (68.8%) 1 (33.3%) 1 (1.7%)
Data are presented as mean±SD unless otherwise stated. COPD: chronic obstructive pulmonary disease;
FEV1: forced expiratory volume in 1 s.
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Alpha-diversity
Figure 2 shows a boxplot of the alpha-diversity metric, Faith’s phylogenetic diversity, by sampling method
and by disease category, excluding the three asthma subjects. The phylogenetic diversity within a sample is
an indication of richness as the diversity increases both when a higher number of different OTUs are
present, and when the phylogenetic distance is larger within the phylogenetic tree (less genetically similar).
Bonferroni-corrected Wilcoxon matched-pairs signed-ranks tests showed that the oral wash samples were
more alpha-diverse than all other sampling methods (p<0.001). The diversity was lower in COPD patients






























FIGURE 1 Mean taxonomic distribution at the phylum level, by sampling method, for all 125 individuals
(unrarefied). OW: oral wash; SVL: small-volume lavage in the left upper lobe; BAL1: first fraction of protected
bronchoalveolar lavage (BAL) from right middle lobe; BAL2: second fraction of protected BAL from right







































FIGURE 2 Box-plot of alpha-diversity measured by wholetree phylogenetic differences grouped according to sampling method and chronic
obstructive pulmonary disease (COPD) status. Rarefied at 1000 sequences. OW: oral wash sample; SVL: small-volume lavage from left upper lobe;
PBAL1: first fraction of protected bronchoalveolar lavage (BAL); PBAL2: second fraction of protected BAL; right PSB: protected specimen brush
from right lower lobe; left PSB: protected specimen brush from left upper lobe.
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were less exposed to potential oral and bronchoscope contamination (OW>SVL>PBAL1>
PBAL2>rightPSB>leftPSB, non-parametric trend test p<0.01).
Beta-diversity
To compare between sample compositions (beta-diversity), we constructed principal coordinates analysis
(PCoA) plots of unweighted UniFrac distances including all procedural samples. Figure 3 shows the PCoA
plots for the oral wash versus each of the other sampling methods. Each dot represents a diversity
measurement for one sample, and the OW sample is always shown in green. As can be seen, most
respiratory tract samples clustered differently from the OW samples, but the visual impression is that the
differences in diversity were smaller between OW and SVL and OW and PBAL samples than for OW and
the PSB samples. Another way of comparing the beta-diversity was employed using a permanova test;
estimating the beta-diversity between OW samples and each of the other sampling methods. This method
tests to which degree the variation in a matrix of UniFrac distances can be explained by an imposed
categorisation (i.e. sampling method). Overall permanova test confirmed that the beta-diversity differed by
sampling method (pseudo F 8.73, p=0.001, 999 permutations). When the distance matrix was split
according to the comparisons in figure 3, all were significant (p<0.01, permanova, corrected for multiple
comparison), with the permanova pseudo F-statistic gradually increasing for the comparison of OW with
SVL, PBAL1, PBAL2, right PSB and left PSB respectively, again indicating that PSB samples were more
clearly separated from OW samples than SVL and PBAL.
Finally we investigated whether the order of sampling (left versus right lung first) influenced alpha- and
beta-diversity in PSB samples. We found no significant difference in alpha- or beta-diversity for the right or
the left PSBs as judged by phylogenetic diversity and unweighted UniFrac (supplementary figures S3 and S4).
Discussion
We have shown that protected BAL and protected brush samples differed more from oral wash samples
than unprotected lavage through the bronchoscope working channel. Thus, unprotected sampling of the
airway microbiome might convey an image of a microbiome that is more similar to the oral microbiome,
than it would have been with protected sampling.
Oral wash
Small volume lavage, LUL
Protected BAL, fraction 1, RML
Protected BAL, fraction 2, RML
Protected brush, RLL
Protected brush, LUL
FIGURE 3 Principal coordinates analyses on unweighted UniFrac distance matrix comparing sampling methods in the MicroCOPD to oral wash
samples. Rarefied at 1000 sequences. LUL: left upper lobe; BAL: bronchoalveolar lavage; RML: right middle lobe; RLL: right lower lobe.
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To our best knowledge this is the first study that presents both protected brush and protected lavage
sampling as compared with both the oral microbiome and unprotected sampling. With more than 120
examined subjects it is by today the largest single site bronchoscopy study of the lung microbiome.
As other authors we find evidence of a lung microbiome separated from the oral microbiome by a larger
fraction of Proteobacteria and a proportionately lower fraction of Firmicutes [2, 8, 15, 20]. However, SEGAL
and associates [3, 4] mainly found that the airway microbiome was characterised by enrichment from
supraglottic areas of the respiratory tract, and in particular by Prevotella and Veillonella OTUs, which are
Bacteriodetes and Firmicutes, respectively. They examined 49 subjects, with supraglottic brushes and BAL
through the working channel, and observed that two clusters dominated airway samples: one dominated
by OTUs present in negative control samples, and one dominated by OTUs present in supraglottic
brushes. One interpretation might be that these two clusters represent two different modalities of
contamination, the first one from laboratory procedures and the second from bronchoscopic carryover.
SEGAL et al. argue that if it was bronchoscopic carry-over, they would have observed a dilutional effect
when they compared a first BAL of the lingula, with the second BAL of the right middle lobe. However,
this comparison was done for only 15 individuals, and anatomically one might expect lower biomass in
the lingula than the right middle lobe.
Other authors have also investigated the possibility of bronchoscopic carryover. BASSIS et al. examined oral
wash samples of 12 subjects and compared them with a first BAL of the lingula and a second BAL of the
right middle lobe [6]. They did not find any difference in quantitative PCR between the first and second
BAL, and no difference in beta-diversity when comparing the OW with the two BALs. Their interpretation
was that if there was significant carryover, there should have been observed some sort of dilutional effect.
Nevertheless, the two sampled sites are separated by the carina, and the bronchoscope must be
repositioned between sampling, and these two sites are indeed in different communication with the
outside world, possibly leading to an a priori larger biomass in the right lung. Also, DICKSON et al.
compared supraglottic brushes with PSB and BAL through the working channel [8]. In principal
component analyses of beta-diversity they found no clustering by sample type, except that the supraglottic
samples differed from the intrapulmonary sample communities. However, by performing unprotected BAL
before PSB, residual BAL fluid might have affected the brush areas making them more similar to the BAL
sample sites. Finally, 15 sampled subjects might not be sufficient to detect the differences we observed in
the current study with more than 100 participants.
It is quite plausible that microbes migrate from the oropharyngeal cavity to the airways, generating a
normal overlap between the oropharyngeal and airway microbiomes [5]. But as we have shown, co-existing
sample contamination likely also is an issue. The oropharyngeal microbiome has a known large biomass,
with a high diversity. By passing through this cavity, contamination to the outside of the bronchoscope
including its tip is inevitable. Use of suction will contaminate the working channel [7]. Since the oral
biomass is much greater than the airway biomass, even a small contamination will have a disproportionate
effect on the supposed airway microbiome if the unprotected measurements are performed through the
working channel. Using the working channel for unprotected lavage repeatedly at different lobes will lead
to contamination from one lobe to another. Using larger volume lavage may negate this effect to some
degree, but not eliminate the problem.
Results from the current study suggest that protected sheet sampling is the superior sampling
methodology. Comparing unprotected SVL and PSB both taken from the upper left lobe in our study, SVL
was most similar to the oral sample by visual assessment of the 10 most abundant taxa, and likewise both
by alpha- and beta-diversity. A direct comparison of protected and unprotected lavage from the same lobe
is impossible, as any washing will impact the contents of later washings. However, the diversity of PBAL
from the right middle lobe was intermediate between that found in OW and that found in the PSB.
Besides the above-mentioned study by DICKSON and colleagues [8], only two other studies have compared
PSBs to other sampling methods [7, 19]. CHARLSON et al. [7] sampled laboratory reagents, the
bronchoscope itself during various parts of the procedure, and the oropharyngeal microbiome in addition
to BAL through the working channel and PSBs. They concluded that the microbiome from the lower
respiratory tract was indiscriminate from the oropharyngeal microbiome irrespective of sampling method.
However, the study included only one PSB per sampling, had lower sequencing depth than the current
study, included only six healthy individuals and there were no adjustments made for OTUs seen in the
negative control samples [7]. HOGAN et al. compared PSB, and SVL samples of nine CF patients [19]. For
eight CF patients who had PSB and SVL taken from the same lobe, diversity was consistently higher in the
PSB samples [19], the opposite of our findings. HOGAN et al. employed the PSB only at visible mucus
plugs, and the airways of adult CF patients are perhaps no longer representing a low biomass
environment. In addition the number of study subjects was limited.
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The main strength of our study was comprehensive sampling of a large, heterogeneous sample of subjects
with and without COPD, while taking precautions to avoid excessive influence from laboratory and
bronchoscopic contamination. However, some potential weaknesses should be acknowledged. First, we
have not performed quantitative PCR, and thus cannot conclude regarding the amount of 16S rRNA gene
copies in the samples before amplification. Second, our analyses do not include a mock community, and
we are therefore not able to provide sequencing error rates for the current study. We could also have
spiked our samples with bacteria that would have indicated the efficiency of our DNA extraction. Third,
pre-bronchoscopy all participants received 0.4 mg salbutamol. This was done for obtaining
pre-bronchoscopy post-bronchodilator lung function values, but had the added benefit of protecting
against procedural bronchospasm. Salbutamol was given as an aerosol through large volume spacers that
are cleaned daily, and we are not aware of reports on contamination through metered dose inhalers.
Furthermore, since both patients and controls received salbutamol, our conclusions should not be affected.
Fourth, some results are difficult to compare with those of other authors because of differences in DNA
extraction, PCR amplification, sequencing and bioinformatic approach. This is the result of a field where
standards for 16S rRNA gene amplicon studies of microbial communities currently do not exist. To
facilitate reproducibility we have used well-documented analytic approaches and mostly default settings for
our bioinformatic pipeline (QIIME), in addition to using primers and PCR recommendations from a
major next-generation sequencing provider (Illumina). Regardless of this, we cannot rule out that some of
our findings only pertain to the current set of methodological choices such as the choice of sequencing
hypervariable region V3V4 [34]. To minimise the influence of small/spurious OTUs we have excluded
singletons by using default settings in our OTU picking, and removed OTUs that constituted less than
0.005% of the total number of sequences.
Insights concerning the airway microbiome in disease and health might provide vital understanding of
disease mechanisms and provide new targets for treating lung diseases such as COPD, asthma, cystic
fibrosis and interstitial lung diseases. However, to date only a minority of studies have performed
protected sampling, and might have been affected by exposure to exposure to microbiota encountered
before reaching the sampled sites. We have shown that unprotected sampling is likely to be affected by this
phenomenon, and we encourage the use of protected specimen brushes when sampling the airway
microbiota.
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